



#### **Corporate Presentation**

#### **Non-Confidential**

Brussels, December 2024



## **Overview**



#### What we do: Accelerating your regulatory journey



#### Our differentiators



#### Contact us







What we do: Accelerating your journey with the best regulatory pathway



Our wide range of service offerings







#### **RLM** proposes guidance on:

**CMC requirements** regarding the manufacturing, characterization, control and stability of the drug substance and drug product

**Preclinical** (proof of concept, pharmacokinetics, toxicology) and **clinical study protocols** required for the approval of different clinical phases

#### **RLM** acts as an applicant for:

Submissions to the EU (EMA and/or National level) and/or the US (FDA)




Our service offerings in **Europe** (EMA and/or National level)



- Briefing documents for Scientific Advice (SA), Protocol assistance, Innovation Task Force (ITF) briefing meeting,...
- Investigational Medicinal Product Dossiers (IMPD) and Investigator's Brochures (IB)
- Clinical Trial Applications (CTA) in CTIS
- Orphan Drug Designations (ODD)
- Pediatric Investigation Plans (PIP)
  - PRIME designation dossiers
- Advanced Therapy Medicinal Product (ATMP) classification and certification
- Preparation of viral safety dossiers



#### Our service offerings in USA (FDA)



Meeting request and briefing book for INTERACT, Type A, B, C, and D meetings

IND (modules 1-5)

- Investigator's Brochures (IB)
- Orphan Drug Designations (ODD) and Rare Pediatric Diseases Designations (RPDD)
- Pediatric Study Plan (PSP)
- Breakthrough Therapy (BT) designation program




Key expertise in RA guidance for development of chemical, biological, and advanced therapy medicinal products:

Vaccines

- Small molecules
- Synthetic peptides
- Monoclonal antibodies (mAbs)

- Live Biotherapeutic Products (LBP) incl. GMOs
- ATMPs: cell therapies, gene therapies and tissue engineering products
- Medical device-drug combination








RLM Consulting can also provide other services internally and via partners:

GxP: SOPs, audits, Qualified Person (QP)

CRO/CDMO: selection and qualification

- Clinical Operations Project Management
- Medical devices
- S Animal health
- Regulatory training
- Due diligence: investment assessment (audits, licensing, partnering, mergers, etc.)





2

## Our differentiators

CYPTI

HEA

droepiandrosterone Irosterone sul dehydroe deoxyribouwieic a osterone deoxy in or respons d X-ray absorptionetry du European Association of Urology electrocardiogram chocardiogram atern Cooperative ronic case repo onic data capti n Organiz: uality of Li

JIII OITIO I





#### **Our differentiators**

Our assets

#### HIGHLY SKILLED

We are a team of **highly skilled scientists (Masters & PhDs) with complimentary degrees:** Biology (Microbiology, Cellular, Molecular,...), Biomedical, Chemistry, Pharmacy, Clinical Research, Infectious Diseases, MBA...



We write your dossiers so you can focus on your product development knowing that we have your regulatory aspects covered.

# INNOVATIVE SOLUTIONS

We strive to find innovative solutions to your challenges so whenever possible we will be creative in our recommendations and strategic guidance to you.



We build long-term relationship with you. We have a small internal turnover, which allows us to have **one project manager per client** that stays together during the entire process.



# **3** CONTACT US



**RLM Consulting** 6, Rue Louis de Geer 1348 Louvain-La-Neuve (BELGIUM)



info@rlmconsulting.be

